Safety of sipavibart as a pre-exposure prophylaxis for COVID-19 in individuals at high risk of developing severe disease: results of the NOVELLA clinical study conducted in the Russian population - PDF (Russian)

Address of the Editorial Office:

• Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

• Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

• Tel.: +7 (926) 905-41-26
• E-mail: e.gorbacheva@ter-arkhiv.ru